Latest Ratios: P/E Ratio 5.6x · EV/EBITDA N/A · ROE -59.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $343M | $565M | $635M | $976M | $2.0B | $4.3B | $1.7B | $297M | $363M | $308M | $338M |
| Enterprise Value | $349M | $570M | $638M | $969M | $2.0B | $4.3B | $1.7B | $278M | $352M | $305M | $337M |
| P/E Ratio → | 5.58 | 9.18 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 15.36 | 25.26 | 23.50 | 47.96 | 73.15 | 209.81 | 224.96 | 39.33 | 49.14 | 59.67 | 120.65 |
| P/B Ratio | 5.06 | 8.32 | 8.82 | 16.79 | 25.29 | 50.31 | 60.54 | 15.74 | 40.71 | 78.28 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 25.51 | 23.59 | 47.60 | 72.38 | 208.07 | 221.26 | 36.71 | 47.66 | 58.95 | 120.26 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 56.6% | 49.1% | 29.4% | 34.9% | 39.3% | 33.2% | 34.4% | 23.9% | 25.4% | -20.0% |
| Operating Margin | -163.9% | -163.9% | -213.6% | -276.1% | -205.4% | -372.9% | -394.7% | -234.2% | -239.2% | -278.9% | -396.0% |
| Net Profit Margin | -186.6% | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | -388.7% | -234.6% | -240.8% | -304.5% | -388.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -59.6% | -59.6% | -65.7% | -86.0% | -75.1% | -135.0% | -125.2% | -127.5% | -276.7% | -399.5% | — |
| ROA | -36.4% | -36.4% | -39.7% | -55.1% | -56.5% | -112.7% | -98.2% | -91.8% | -169.2% | -290.8% | -243.3% |
| ROIC | -37.2% | -37.2% | -69.1% | -76.9% | -78.5% | -229.8% | — | — | — | — | — |
| ROCE | -36.1% | -36.1% | -62.0% | -61.2% | -61.0% | -133.3% | -125.3% | -125.2% | -274.9% | -589.9% | -512.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.47 | 0.47 | 0.42 | 0.51 | 0.35 | 0.00 | 0.02 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.08 | 0.03 | -0.12 | -0.27 | -0.42 | -1.00 | -1.05 | -1.23 | -0.94 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.91 | -10.91 | -601.50 | -92.04 | -22.48 | -886.60 | -610.27 | -655.74 | -982.67 | -84.32 | -541.60 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.73 | 3.73 | 2.44 | 3.79 | 3.39 | 3.17 | 4.85 | 4.39 | 2.58 | 2.01 | 1.00 |
| Quick Ratio | 3.27 | 3.27 | 2.15 | 3.38 | 2.98 | 2.74 | 4.53 | 4.12 | 2.31 | 1.61 | 0.70 |
| Cash Ratio | 2.82 | 2.82 | 1.71 | 2.95 | 2.55 | 2.50 | 4.06 | 3.94 | 2.13 | 1.32 | 0.45 |
| Asset Turnover | — | 0.20 | 0.23 | 0.21 | 0.23 | 0.20 | 0.21 | 0.31 | 0.52 | 0.74 | 0.72 |
| Inventory Turnover | 2.25 | 2.25 | 2.90 | 2.84 | 2.26 | 2.00 | 2.21 | 3.51 | 4.09 | 3.26 | 3.79 |
| Days Sales Outstanding | — | 43.60 | 72.24 | 65.33 | 84.68 | 31.78 | 82.10 | 34.38 | 11.55 | 30.71 | 37.76 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 17.9% | 10.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $50M | $40M | $28M | $24M | $17M | $6M | $2M | $1M | $481412 | $260148 |
Insufficient capital runway
Based on current market data, DRIO trades at a price-to-sales multiple of 15.36, which appears significantly detached from the company's 17.31% year-over-year revenue contraction and suggests that investors may be mispricing the firm's transition to a B2B model relative to its actual growth trajectory.
The elevated P/S ratio implies that the market is still assigning a premium for a high-growth SaaS narrative that the current financial performance fails to support. Given the persistent operating losses and declining top-line, this valuation warrants further investigation as it may be vulnerable to a sharp re-rating if the company fails to demonstrate a clear path to revenue stabilization.
As reported in recent financial statements, DarioHealth's ROIC has trended into negative territory, reaching -7.4% in 2026Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its platform-centric investments and ongoing operational pivot.
The inability to generate positive returns on invested capital suggests that the capital allocated toward platform development and customer acquisition is not yet yielding sufficient incremental margins. Investors should monitor whether this trend is structural or merely a temporary byproduct of the heavy R&D spending required to maintain the company's multi-condition integrated platform.
According to quarterly filings, the company's cash conversion cycle has remained elevated at 79 days in 2026Q1, reflecting persistent challenges in managing inventory and collecting receivables effectively as the firm attempts to navigate the transition from direct-to-consumer hardware sales to B2B service contracts.
The high days inventory outstanding, which reached 160 days in the most recent quarter, suggests that the company is struggling to optimize its supply chain for its proprietary hardware components. This inefficiency ties up critical liquidity that could otherwise be used to fund operations, further exacerbating the company's reliance on external capital.
Based on the latest balance sheet data, the current ratio of 3.04 provides a superficial appearance of liquidity, yet the company's consistent cash burn and negative operating margins suggest that its actual runway is far more constrained than the headline ratio might imply to casual observers.
While the current ratio appears healthy compared to historical levels, it is heavily influenced by non-cash assets and inventory that may not be easily liquidated in a stress scenario. The rapid depletion of cash reserves warrants further investigation, as the company may be forced to seek dilutive financing if the current burn rate persists.
The most commonly misapplied metric for DarioHealth is the price-to-sales ratio, which obscures the company's high hardware-related cost of goods sold and the significant portion of revenue that is non-recurring, leading to an inflated perception of the firm's true software-driven earning power.
Investors should instead focus on the ratio of gross profit to customer acquisition costs or a more granular breakdown of recurring subscription revenue versus transactional hardware sales. Relying on a standard P/S multiple for a company in this stage of transition risks ignoring the underlying margin pressure and the potential for future impairment of intangible assets.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DRIO stock.
DarioHealth Corp.'s current P/E ratio is 5.6x. The historical average is 9.2x.
DarioHealth Corp.'s return on equity (ROE) is -59.6%. The historical average is -150.0%.
Based on historical data, DarioHealth Corp. is trading at a P/E of 5.6x. Compare with industry peers and growth rates for a complete picture.
DarioHealth Corp. has 56.6% gross margin and -163.9% operating margin.